Researchers at the University of Kansas Cancer Center have received a $4.2 million, five-year grant from NCI to study the effects of bazedoxifene and low-dose conjugated estrogen in women who are at increased risk for developing breast cancer and are experiencing menopausal symptoms.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
